SERVICES - Breast 360 Breast Cancer Screening
Early detection can change everything—before symptoms ever appear.
Be Proactive: Early Screening Can Save Lives
The American Cancer Society reports that when breast cancer is detected early (before it spreads), the survival rate is about 99%.
The DNA Breast 360 test looks for two proteins in your tears—S100A8 (Calgranulin A) and S100A9 (Calgranulin B). These proteins are linked to inflammation in the body and can be elevated in people with breast cancer. Detecting these markers may help identify potential concerns earlier, giving you the chance to take action sooner.
Gain Peace of Mind
If you are worried about your breast cancer risk due to family history or genetics, the DNA Breast 360 test may provide helpful information.
Research shows the test has about 92% sensitivity for detecting clinically significant activity associated with breast cancer. This means it may help identify potential problems early, allowing for earlier monitoring, treatment, or preventive care.
Even if the results indicate a concern, the information can help you and your healthcare provider take the next steps toward protecting your health.
Use It Alongside Regular Screening
The DNA Breast 360 test is designed to complement—not replace—traditional screening methods such as mammograms or imaging.
Because breast cancer treatments are most effective when started early, regular screening is important. This simple, non-invasive test can serve as an additional early warning tool, especially for:
Younger women
People with limited access to regular imaging
Anyone wanting additional insight into their breast health
Understanding Your Results
Your results will be reported as either:
Negative – No clinically significant biomarkers detected
Clinically Significant – Biomarkers associated with breast cancer were detected
Important notes:
A clinically significant result is not a cancer diagnosis.
False positives and false negatives are possible.
You will have the opportunity to discuss your results with one of the program’s clinicians or your own healthcare provider to determine the appropriate next steps.
